Search results for "PIO"

showing 10 items of 2238 documents

Measurement of the muon neutrino inclusive charged-current cross section in the energy range of 1–3 GeV with the T2K INGRID detector

2016

International audience; We report a measurement of the $\nu_{\mu}$-nucleus inclusive charged current cross section (=$\sigma^{cc}$) on iron using data from exposed to the J-PARC neutrino beam. The detector consists of 14 modules in total, which are spread over a range of off-axis angles from 0$^\circ$ to 1.1$^\circ$. The variation in the neutrino energy spectrum as a function of the off-axis angle, combined with event topology information, is used to calculate this cross section as a function of neutrino energy. The cross section is measured to be $\sigma^{cc}(1.1\text{ GeV}) = 1.10 \pm 0.15$ $(10^{-38}\text{cm}^2/\text{nucleon})$, $\sigma^{cc}(2.0\text{ GeV}) = 2.07 \pm 0.27$ $(10^{-38}\te…

COLLISIONSNuclear and High Energy PhysicsParticle physicsMULTIPLICITY DISTRIBUTIONSPhysics::Instrumentation and Detectors530 PhysicsFOS: Physical sciencesneutrino scatteringAstronomy & Astrophysics01 natural sciences7. Clean energyHigh Energy Physics - ExperimentPhysics Particles & FieldsNuclear physicsHigh Energy Physics - Experiment (hep-ex)Cross section (physics)0202 Atomic Molecular Nuclear Particle And Plasma PhysicsMONTE-CARLO0103 physical sciencesPION ABSORPTION[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Muon neutrino010306 general physicsNuclear Experiment0206 Quantum PhysicsCharged currentPhysicsRange (particle radiation)Science & TechnologyNUCLEIhep-ex010308 nuclear & particles physicsPhysicsneutrinoscross sectionsNuclear & Particles Physics0201 Astronomical And Space SciencesPhysical SciencesSIMULATIONHigh Energy Physics::ExperimentNeutrinoNucleonEvent (particle physics)Energy (signal processing)
researchProduct

Lung deposition of extrafine vs non-extrafine triple therapies in patients with COPD using Functional Respiratory Imaging (FRI)

2019

Introduction: FRI is a validated computational fluid dynamics (CFD)-based technique using aerosol delivery performance profile, patients’ high-resolution lung CT scans and patient-derived inhalation profiles to simulate aerosol lung deposition. Aims and Objectives: To evaluate lung deposition patterns of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium [BDP/FF/G; TRIMBOW®] pressurized metered dose inhaler (pMDI) and non-extrafine fluticasone furoate/vilanterol/umeclidinium [FluF/VI/UMEC; TRELEGY® ELLIPTA®] dry powder inhaler (DPI) in patients with stable COPD and moderate to very severe airflow obstruction. Methods: Intrathoracic depositions of the inhaled corticoster…

COPDmedicine.medical_specialtyInhalationbusiness.industryInhalerUrologyBeclometasone dipropionaterespiratory systemmedicine.diseaseMetered-dose inhalerFluticasone propionateDry-powder inhalerchemistry.chemical_compoundchemistryMedicineVilanterolbusinessmedicine.drugImaging
researchProduct

EL ARTÍCULO 324 DEL CÓDIGO ORGÁNICO DE TRIBUNALES Y EL PRINCIPIO DE IGUALDAD EN EL ORDENAMIENTO JURÍDICO CHILENO

2005

El presente artículo analiza la norma contenida en el inciso segundo del art. 324 del Código Orgánico de Tribunales y su correspondencia con la Constitución Política. Tradicionalmente dicha norma se ha entendido, en la doctrina y jurisprudencia nacionales, como una auténtica excepción al principio general que orienta la aplicación de la ley penal en relación a las personas. A partir del desarrollo que el principio de igualdad ha experimentado en la evolución del Estado moderno, y de su reconocimiento en el Derecho constitucional chileno, se llega a establecer la incompatibilidad de la norma en cuestión con el mencionado principio This paper examines the rule embodied in the second paragraph…

CRIMINAL LAWAPLICACIÓN DE LA LEY PENAL EN CUANTO A LAS PERSONASCRIMINAL LAW APPLICATION REGARDING PERSONS WITHIN ITS SCOPEDERECHO PENALPRINCIPLE OF EQUALITYPRINCIPIO DE IGUALDADLaw
researchProduct

Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by …

2013

The fatty acids, n-butyric acid (BA), 4-phenylbutyric acid (PBA) and valproic acid (VPA, 2-propylpentanoic acid) have been used for many years in the treatment of a variety of CNS and peripheral organ diseases including cancer. New information that these drugs alter epigenetic processes through their inhibition of histone deacetylases (HDACs) has renewed interest in their biodistribution and pharmacokinetics and the relationship of these properties to their therapeutic and side effect profiles. In order to determine the pharmacokinetics and biodistribution of these drugs in primates, we synthesized their carbon-11 labeled analogues and performed dynamic positron emission tomography (PET) in…

Cancer ResearchBiodistributionSide effectPharmacologyPhenylbutyrateArticleButyric acidchemistry.chemical_compoundPharmacokineticsmedicineAnimalsRadiology Nuclear Medicine and imagingTissue DistributionCarbon RadioisotopesValproic AcidRadiochemistryValproic AcidBrainLipid metabolismBlood ProteinsBlood proteinsPhenylbutyratesHistone Deacetylase InhibitorschemistryIsotope LabelingPositron-Emission TomographyMolecular MedicineButyric AcidFemalemedicine.drugPapio
researchProduct

Reinvestigation of the synthesis and evaluation of [N-methyl-11C]vorozole, a radiotracer targeting cytochrome P450 aromatase

2009

Abstract Introduction We reinvestigated the synthesis of [ N -methyl- 11 C]vorozole, a radiotracer for aromatase, and discovered the presence of an N -methyl isomer which was not removed in the original purification method. Herein we report the preparation and positron emission tomography (PET) studies of pure [ N -methyl- 11 C]vorozole. Methods Norvorozole was alkylated with [ 11 C]methyl iodide as previously described and also with unlabeled methyl iodide. A high-performance liquid chromatography (HPLC) method was developed to separate the regioisomers. Nuclear magnetic resonance (NMR) spectroscopy ( 13 C and 2D-nuclear Overhauser effect spectroscopy NMR) was used to identify and assign s…

Cancer ResearchMagnetic Resonance SpectroscopyTime FactorsAlkylationStereochemistryStereoisomerismNuclear Overhauser effectAlkylationHigh-performance liquid chromatographyArticlechemistry.chemical_compoundAromatasemedicineStructural isomerAnimalsRadiology Nuclear Medicine and imagingHydrocarbons IodinatedRadioactive TracersChromatography High Pressure LiquidChemistryBrainStereoisomerismNuclear magnetic resonance spectroscopyTriazolesPositron-Emission TomographyVorozoleMolecular MedicineFemalePapiomedicine.drugMethyl iodideNuclear Medicine and Biology
researchProduct

A randomised controlled study on the use of anti-inflammatory drugs in patients with cancer pain on morphine therapy

2002

The role of non-steroidal anti-inflammatory drugs (NSAIDs) in cancer pain has been well established in the treatment of mild pain and in association with opioids in the treatment of moderate to severe pain. The aim of this study was to verify the effects of NSAIDs on morphine escalation in advanced cancer patients with pain followed-up at home and to assess the pharmacoeconomic implications. A prospective randomised controlled study was carried out in 156 consecutive advanced cancer patients with pain followed-up at home in the period December 1999–December 2000. In this group of patients, 47 were selected with pain progression after 1 week of opioid stabilisation. Patients were randomly as…

Cancer ResearchPalliative carePerformance statusbusiness.industryKetorolacOncologyOpioidAnesthesiaMorphineMedicineIntractable painbusinessCancer painAdverse effectmedicine.drugEuropean Journal of Cancer
researchProduct

The prevalence and characteristics of breakthrough cancer pain in patients receiving low doses of opioids for background pain

2021

Simple Summary The aim of this study was to assess the prevalence and characteristics of breakthrough cancer pain (BTcP) in patients receiving low doses of opioids for background pain. This prospective study showed that in this population, BTcP prevalence was 69.8%. Many patients did not achieve a sufficient level of satisfaction with BTcP medications, particularly with oral morphine. Data also suggest that better optimization of background analgesia, though apparently acceptable, may limit the number of BTcP episodes. Abstract The aim of this study was to assess the prevalence and characteristics of breakthrough cancer pain (BTcP) in patients receiving low doses of opioids for background p…

Cancer Researchmedicine.medical_specialtyPain relieflcsh:RC254-282ArticleCONSECUTIVE SAMPLE03 medical and health sciences0302 clinical medicineAnalgesic therapyInternal medicineEpidemiologymedicineIn patientOral morphinebreakthrough cancer pain; opioids; dosesbusiness.industryLow doseBreakthrough cancer painlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensdosesOpioidsOncologyDose030220 oncology & carcinogenesisCancer painbusiness030217 neurology & neurosurgery
researchProduct

Episodic Breathlessness with and without Background Dyspnea in Advanced Cancer Patients Admitted to an Acute Supportive Care Unit

2020

Aim: To characterize episodic breathlessness (EB) in patients with advanced cancer, and to determine factors influencing its clinical appearance. Methods: A consecutive sample of advanced cancer patients admitted to an acute palliative care unit was surveyed. Continuous dyspnea and EB were measured by a numerical scale. The use of drugs used for continuous dyspnea and EB was recorded. Patients were asked about the characteristics of EB (frequency, intensity, duration and triggers). The Multidimensional dyspnea profile (MDP), the Brief dyspnea inventory (BDI), the Athens sleep scale (AIS) and the Hospital Anxiety and Depression Scale (HADS) were also administered. Results: From 439 advanced …

Cancer Researchmedicine.medical_specialtyPalliative careEpisodic breathlessneOpioidHospital Anxiety and Depression Scalelcsh:RC254-282ArticleCONSECUTIVE SAMPLE03 medical and health sciences0302 clinical medicineInternal medicineMedicineadvanced cancerIn patient030212 general & internal medicinepalliative carebusiness.industryopioidsClinical appearancedyspneaPalliative care.lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensAdvanced cancerConfidence intervalrespiratory tract diseasesepisodic breathlessnessOncology030220 oncology & carcinogenesisbusinessCancers
researchProduct

Delphi Consensus on the Follow-up of Cancer Patients with Breakthrough Pain Under Opioid Treatment

2019

e23135 Background: Breakthrough cancer pain (BTcP) is one of the most common symptoms related with the disease and its treatment. Its management differs from that of chronic pain but there is not a wide consensus about fundamental aspects of BTcP definition, diagnosis, follow-up, and management. The objective of this study promoted by ECO Foundation, is to reach a consensus on the follow-up of patients with BTcP under opioid treatment. Methods: This work was conducted using a modified Delphi method organized in two rounds and involving a panel of 84 medical oncologists. A questionnaire of 66 items was developed. The items proposed to reach a consensus included the following topics: 1) When…

Cancer Researchmedicine.medical_specialtybusiness.industryBreakthrough PainChronic painCancerDiseasemedicine.diseaseOncologyOpioidPain controlInternal medicineMedicinebusinessIntensive care medicineCancer paincomputerDelphimedicine.drugcomputer.programming_languageSN Comprehensive Clinical Medicine
researchProduct

Synthesis and PET studies of [11C-cyano]letrozole (Femara®), an aromatase inhibitor drug

2009

Abstract Introduction Aromatase, a member of the cytochrome P 450 family, converts androgens such as androstenedione and testosterone into estrone and estradiol, respectively. Letrozole (1-[bis-(4-cyanophenyl)methyl]-1 H -1,2,4-triazole; Femara) is a high-affinity aromatase inhibitor ( K i =11.5 nM) that has Food and Drug Administration approval for breast cancer treatment. Here we report the synthesis of carbon-11-labeled letrozole and its assessment as a radiotracer for brain aromatase in the baboon. Methods Letrozole and its precursor (4-[(4-bromophenyl)-1 H -1,2,4-triazol-1-ylmethyl]benzonitrile) were prepared in a two-step synthesis from 4-cyanobenzyl bromide and 4-bromobenzyl bromide,…

Cancer Researchmedicine.medical_specialtymedicine.drug_classEstronePharmacologyArticlechemistry.chemical_compoundAromatasePharmacokineticsInternal medicineNitrilesmedicineAnimalsRadiology Nuclear Medicine and imagingAndrostenedioneCarbon RadioisotopesAromataseTestosteroneAromatase inhibitorbiologyChemistryAromatase InhibitorsLetrozoleBrainTriazolesEndocrinologyFree fractionIsotope LabelingPositron-Emission TomographyLetrozolebiology.proteinMolecular MedicineFemaleRadiopharmaceuticalsmedicine.drugPapio
researchProduct